IL-12 gene therapy for cancer: In synergy with other immunotherapies

Ignacio Melero, Guillermo Mazzolini, Iñigo Narvaiza, Cheng Qian, Lieping Chen, Jesús Prieto

Research output: Contribution to journalArticle

Abstract

In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.

Original languageEnglish (US)
Pages (from-to)113-115
Number of pages3
JournalTrends in Immunology
Volume22
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Interleukin-12
Genetic Therapy
Immunotherapy
Neoplasm Genes
Cell- and Tissue-Based Therapy
Chemokines
Neoplasms
Hand
Cytokines
Genes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Melero, I., Mazzolini, G., Narvaiza, I., Qian, C., Chen, L., & Prieto, J. (2001). IL-12 gene therapy for cancer: In synergy with other immunotherapies. Trends in Immunology, 22(3), 113-115. https://doi.org/10.1016/S1471-4906(00)01824-X

IL-12 gene therapy for cancer : In synergy with other immunotherapies. / Melero, Ignacio; Mazzolini, Guillermo; Narvaiza, Iñigo; Qian, Cheng; Chen, Lieping; Prieto, Jesús.

In: Trends in Immunology, Vol. 22, No. 3, 2001, p. 113-115.

Research output: Contribution to journalArticle

Melero, I, Mazzolini, G, Narvaiza, I, Qian, C, Chen, L & Prieto, J 2001, 'IL-12 gene therapy for cancer: In synergy with other immunotherapies', Trends in Immunology, vol. 22, no. 3, pp. 113-115. https://doi.org/10.1016/S1471-4906(00)01824-X
Melero, Ignacio ; Mazzolini, Guillermo ; Narvaiza, Iñigo ; Qian, Cheng ; Chen, Lieping ; Prieto, Jesús. / IL-12 gene therapy for cancer : In synergy with other immunotherapies. In: Trends in Immunology. 2001 ; Vol. 22, No. 3. pp. 113-115.
@article{bdf9b5a66542485eb46c22ffa49e883b,
title = "IL-12 gene therapy for cancer: In synergy with other immunotherapies",
abstract = "In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.",
author = "Ignacio Melero and Guillermo Mazzolini and I{\~n}igo Narvaiza and Cheng Qian and Lieping Chen and Jes{\'u}s Prieto",
year = "2001",
doi = "10.1016/S1471-4906(00)01824-X",
language = "English (US)",
volume = "22",
pages = "113--115",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - IL-12 gene therapy for cancer

T2 - In synergy with other immunotherapies

AU - Melero, Ignacio

AU - Mazzolini, Guillermo

AU - Narvaiza, Iñigo

AU - Qian, Cheng

AU - Chen, Lieping

AU - Prieto, Jesús

PY - 2001

Y1 - 2001

N2 - In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.

AB - In preclinical models of cancer, gene therapy with interleukin 12 (IL-12) has reached unprecedented levels of success when combined with immunotherapy approaches such as gene transfer of other cytokines and/or chemokines, costimulatory molecules or adoptive cell therapy. These combinations have been found to produce synergistic rather than additive effects. Meanwhile, IL-12 gene therapy is beginning clinical testing as a single agent, but combination strategies are at hand.

UR - http://www.scopus.com/inward/record.url?scp=0034918717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034918717&partnerID=8YFLogxK

U2 - 10.1016/S1471-4906(00)01824-X

DO - 10.1016/S1471-4906(00)01824-X

M3 - Article

C2 - 11286714

AN - SCOPUS:0034918717

VL - 22

SP - 113

EP - 115

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 3

ER -